Medicine Iontophoresis Market To See Huge Growth By 2021-2027
Market Drivers for Iontophoresis in Medicine
The Medicine Iontophoresis Market is projected to rise as people become more aware of how to treat hyperhidrosis. For example, the International Hyperhidrosis Society (IHhS) in the United States commemorates November is Hyperhidrosis Awareness Month by producing documentaries, conducting patient interviews, and arranging other events to raise public awareness of hyperhidrosis.
Furthermore, rising research into the use of iontophoresis in the treatment of numerous diseases and symptoms is projected to propel the Medicine Iontophoresis Market forward. For example, in April 2018, EyeGate Pharma Company created EyeGate II iontophoresis, a unique ocular medication delivery system in which an electric current generated in the device delivers ionised medicine into the eye, which is then absorbed by the electric current.
Iontophoresis is a method of delivering a drug or other compounds through the skin using an electric current. Iontophoresis is frequently recommended for persons who suffer from hyperhidrosis (excessive sweating) of the hands and/or feet since it helps to reduce sweating. Acetic acid (calcific tendinitis), calcium chloride and magnesium sulphate (musculoskeletal spasm control), dexamethasone (inflammation), lidocaine (soft tissue inflammation), and zinc oxide are all good candidates for iontophoresis (rheumatoid arthritis).
Market Restraints for Medicine Iontophoresis
Medicine Iontophoresis Market is projected to be limited by side effects and restrictions related with the therapy. According to a 2016 research by the British Association of Dermatologists, people frequently complain of bruising or blisters when the current strength is too high for iontophoresis, a minor burning sensation when the electrode is touched, and irritation in the treated area after treatment. Furthermore, iontophoresis is not recommended for people who have cardiac pacemakers or metal implants.
Furthermore, product recalls due to non-compliance with regulatory norms are likely to stifle the market for pharmaceutical iontophoresis. For example, Health Canada recalled IONTODERMA ID-1000, a product of IONTODERMA, in August 2016 due to a failure to comply with medical device laws and the sale of medical devices without an appropriate authorization.
Read more @
Comments
Post a Comment